BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3085 related articles for article (PubMed ID: 32249203)

  • 1. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
    Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK
    J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
    Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
    Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.
    Chun J; Cho Y; Park KH; Choi H; Cho H; Lee HJ; Jang H; Kim KH; Oh YK; Kim YB
    J Microbiol Biotechnol; 2019 May; 29(5):813-819. PubMed ID: 30982320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
    Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
    Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
    Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
    Wirblich C; Coleman CM; Kurup D; Abraham TS; Bernbaum JG; Jahrling PB; Hensley LE; Johnson RF; Frieman MB; Schnell MJ
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
    Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
    PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
    Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
    Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
    Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
    Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
    Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
    Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
    Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.
    Deng Y; Lan J; Bao L; Huang B; Ye F; Chen Y; Yao Y; Wang W; Qin C; Tan W
    Emerg Microbes Infect; 2018 Apr; 7(1):60. PubMed ID: 29618723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
    Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF
    Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.
    Kim E; Okada K; Kenniston T; Raj VS; AlHajri MM; Farag EA; AlHajri F; Osterhaus AD; Haagmans BL; Gambotto A
    Vaccine; 2014 Oct; 32(45):5975-82. PubMed ID: 25192975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 155.